Artificial Intelligence (AI) is making a significant impact on the field of drug discovery. One of the challenges in this field is finding compounds with the right characteristics for drug development, such as absorption, distribution, metabolism, extraction, and toxicity (ADMET). Traditional screening methods can be slow and imprecise, leaving room for improvement.
To address this issue, the researchers at Stanford University and Greenstone Biosciences have developed an advanced AI platform called ADMET-AI. This platform uses a graph neural network called Chemprop-RDKit to rapidly and accurately predict ADMET properties for large chemical libraries.
ADMET-AI has shown impressive performance by outperforming other prediction tools in speed and accuracy. Its unique features include making predictions on batches of molecules and providing contextualized predictions based on a set of approved drugs.
The platform’s architecture and integration of Chemprop-RDKit have allowed it to predict a wide range of ADMET properties with high accuracy. It excels in regression and classification tasks and is significantly faster than other ADMET web servers. The local version of ADMET-AI can process a million molecules in just 3.1 hours.
In conclusion, ADMET-AI is revolutionizing drug discovery by providing a fast, precise, and adaptable platform for analyzing large chemical libraries. It meets the growing demand for an effective screening tool and represents a significant leap in identifying drug candidates with optimum ADMET profiles for further development.
For more information, you can check out the research paper, project, and code on the respective links. If you like the work, you can subscribe to the newsletter for more updates on AI in drug discovery.